AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27291997 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaratumab (15 mg/kg) plus doxorubicin (75 mg/m²)
Number of subjects: 148
Study 27291997 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m²) alone
Number of subjects: 148
Study 25274252 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise only
Number of subjects: 45
Study 25274252 — intervention group
Group type: EXPERIMENTAL
Intervention: rigid anti-pronation tape and exercise
Number of subjects: 45
Study 25274252 — intervention group
Group type: EXPERIMENTAL
Intervention: elastic anti-pronation tape and exercise
Number of subjects: 45
Study 22762137 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin 5×/week
Number of subjects: 379
Study 22762137 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin 3×/week
Number of subjects: 379
Study 22762137 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5×/week
Number of subjects: 379
Study 20883410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 9
Study 20883410 — intervention group
Group type: COMPARATOR
Intervention: Non-tamoxifen treatment
Number of subjects: 9
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255
Study 17628686 — intervention group
Group type: COMPARATOR
Intervention: no immediate treatment
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: higher baseline IOP
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: lower baseline IOP
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline predictors
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: lower ocular systolic perfusion pressure
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: cardiovascular disease history (higher baseline IOP)
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: lower systolic blood pressure (lower baseline IOP)
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP levels at follow‐up
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: disc hemorrhages
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: thinner central corneal thickness (CCT)
Number of subjects: 255
Study 17628686 — intervention group
Group type: EXPERIMENTAL
Intervention: thinner CCT (higher baseline IOP)
Number of subjects: 255
Study 15982124 — intervention group
Group type: EXPERIMENTAL
Intervention: Opponent color pairs (e.g., the word BLUE in yellow)
Number of subjects: 0
Study 15982124 — intervention group
Group type: COMPARATOR
Intervention: Nonopponent color pairs (e.g., BLUE in red)
Number of subjects: 0
Study 15982124 — intervention group
Group type: EXPERIMENTAL
Intervention: Farnsworth‐Munsell 100‐Hue Test
Number of subjects: 0
Study 15982124 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network simulations
Number of subjects: 0
Study 12699401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast 225mg twice daily
Number of subjects: 0
Study 12699401 — intervention group
Group type: COMPARATOR
Intervention: Pranlukast 225mg twice daily plus halved dosage of inhaled corticosteroid
Number of subjects: 0
Study 12699401 — intervention group
Group type: COMPARATOR
Intervention: Pranlukast
Number of subjects: 0
Study 11235009 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble board training
Number of subjects: 44
Study 11235009 — intervention group
Group type: COMPARATOR
Intervention: Jump landing training
Number of subjects: 44
Study 11235009 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 44
Study 11235009 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Wobble board, Jump landing, and Control)
Number of subjects: 44
Study 9139306 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil (RPO) supplement (2400 mu g of beta-carotene)
Number of subjects: 24
Study 9139306 — intervention group
Group type: COMPARATOR
Intervention: Control group (600 mu g of oral vitamin A palmitate)
Number of subjects: 24
Study 1479004 — intervention group
Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 50
Study 1479004 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation
Number of subjects: 50
Study 1479004 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation (AID)
Number of subjects: 50
Study 1479004 — intervention group
Group type: COMPARATOR
Intervention: Ovarian stimulation (non-AID)
Number of subjects: 50
Study 3909379 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (256 micrograms daily in selenium-enriched yeast)
Number of subjects: 40
Study 3909379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30658773 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drainage device (drain group, n=50)
Number of subjects: 100
Study 30658773 — intervention group
Group type: COMPARATOR
Intervention: No drain (control group, n=50)
Number of subjects: 100
Study 30658773 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 100
Study 30658773 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain cohort
Number of subjects: 100
Study 28900690 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 114
Study 26549704 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone topical solution 2% (60 mg daily, applied to axillae)
Number of subjects: 148
Study 24462419 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 75
Study 24462419 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 75
Study 24462419 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac
Number of subjects: 75
Study 22474059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg rtPA
Number of subjects: 64
Study 22474059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg rtPA
Number of subjects: 64
Study 22474059 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg rtPA
Number of subjects: 64
Study 22474059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19664255 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief structured advice
Number of subjects: 744
Study 19664255 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lifestyle counselling
Number of subjects: 744
Study 19664255 — intervention group
Group type: COMPARATOR
Intervention: Leaflet-only control group
Number of subjects: 744
Study 17578505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 32
Study 17578505 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor-based immunosuppression
Number of subjects: 32
Study 17578505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 32
Study 15159685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pancreatitis
Number of subjects: 3
Study 15159685 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractures
Number of subjects: 3
Study 15159685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pain groups (acute pancreatitis and fractures)
Number of subjects: 3
Study 15159685 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without pain)
Number of subjects: 3
Study 15159685 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study 12622078 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herb group
Number of subjects: 10
Study 12622078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 9792567 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter therapy
Number of subjects: 22
Study 9792567 — intervention group
Group type: COMPARATOR
Intervention: Standard manual chest physiotherapy (CPT)
Number of subjects: 22
Study 7521992 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antithyroid drugs 6 days before radioiodine therapy
Number of subjects: 21
Study 7521992 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (131I)
Number of subjects: 21
Study 7521992 — intervention group
Group type: COMPARATOR
Intervention: No antithyroid drugs (control group)
Number of subjects: 21
Study 2674262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen), 1.0 mg twice daily
Number of subjects: 138
Study 2674262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen)
Number of subjects: 138
Study 2674262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 834152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 3.2 g daily for 4 days
Number of subjects: 26
Study 834152 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (ID) 300 mg daily for 4 days
Number of subjects: 26
Study 834152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Acetylsalicylic acid (ASA) 1.5 g
Number of subjects: 26
Study 834152 — intervention group
Group type: COMPARATOR
Intervention: Acute Indomethacin (ID) 100 mg
Number of subjects: 26
Study 31354089 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation plus pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 692
Study 31354089 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 692
Study 31354089 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular reflux at 12 months
Number of subjects: 692
Study 31354089 — intervention group
Group type: EXPERIMENTAL
Intervention: CFV non-compressibility at 1 month
Number of subjects: 692
Study 31354089 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular reflux prevalence
Number of subjects: 692
Study 28455082 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 46
Study 28455082 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 46
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 100 μg once daily
Number of subjects: 0
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 400 μg once daily
Number of subjects: 0
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 800 μg once daily
Number of subjects: 0
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 100 μg twice daily
Number of subjects: 0
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 200 μg twice daily
Number of subjects: 0
Study 26286203 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 400 μg twice daily
Number of subjects: 0
Study 24722530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial (131)I-lipiodol (2,200 MBq)
Number of subjects: 58
Study 24722530 — intervention group
Group type: COMPARATOR
Intervention: Unlabeled lipiodol
Number of subjects: 58
Study 21852093 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP/NX)
Number of subjects: 150
Study 20014651 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversing with each other on rigid surface
Number of subjects: 2
Study 20014651 — intervention group
Group type: COMPARATOR
Intervention: Conversing with confederates on rigid surface
Number of subjects: 2
Study 20014651 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversing with each other on nonrigid surface
Number of subjects: 2
Study 20014651 — intervention group
Group type: COMPARATOR
Intervention: Conversing with confederates on nonrigid surface
Number of subjects: 2
Study 20014651 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversing on nonrigid surface
Number of subjects: 2
Study 17516972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (target dBP, 85 mmHg)
Number of subjects: 132
Study 17516972 — intervention group
Group type: COMPARATOR
Intervention: Less tight control (target dBP, 100 mmHg)
Number of subjects: 132
Study 14736130 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 16
Study 14736130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11194219 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and social support intervention (n = 250)
Number of subjects: 502
Study 11194219 — intervention group
Group type: COMPARATOR
Intervention: Wait‐listed control group (n = 252)
Number of subjects: 502
Study 9886747 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 138
Study 9886747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with significant stenosis
Number of subjects: 138
Study 9886747 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 138
Study 7731414 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (CF children with symptoms)
Number of subjects: 20
Study 7731414 — intervention group
Group type: COMPARATOR
Intervention: Group B (CF children without symptoms)
Number of subjects: 20
Study 7731414 — intervention group
Group type: COMPARATOR
Intervention: Group C (healthy children)
Number of subjects: 20
Study 2500055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 100
Study 2500055 — intervention group
Group type: COMPARATOR
Intervention: Sodium chondroitin sulfate-sodium hyaluronate
Number of subjects: 100
Study 218151 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and cyclic progesterone
Number of subjects: 168
Study 218151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 31220140 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder intervention
Number of subjects: 506
Study 31220140 — intervention group
Group type: EXPERIMENTAL
Intervention: Second SMS message intervention
Number of subjects: 506
Study 31220140 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study 28388953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with the test product (novel combination vaccine consisting of PCV2 subunits and inactivated M. hyo strain J)
Number of subjects: 600
Study 28388953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with the test product (novel combination vaccine)
Number of subjects: 600
Study 28388953 — intervention group
Group type: COMPARATOR
Intervention: Control group (injected with sterile buffered saline)
Number of subjects: 600
Study 26302093 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/day for 1 month)
Number of subjects: 0
Study 26302093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23644038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy for 16 weeks
Number of subjects: 231
Study 23644038 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 16 weeks
Number of subjects: 231
Study 23644038 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 231
Study 21318601 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 152
Study 21318601 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose-dense chemotherapy
Number of subjects: 152
Study 21318601 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiogenesis markers (CD31 and CD105)
Number of subjects: 152
Study 21318601 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular subtypes analysis
Number of subjects: 152
Study 21318601 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tumor size and positive Her-2 status
Number of subjects: 152
Study 18448859 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3/6 fatty acids (eye q) for 6 months
Number of subjects: 75
Study 18448859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 17389292 — intervention group
Group type: EXPERIMENTAL
Intervention: IV IL-2
Number of subjects: 159
Study 17389292 — intervention group
Group type: EXPERIMENTAL
Intervention: SC IL-2
Number of subjects: 159
Study 17389292 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 159
Study 15009002 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy without cranial irradiation
Number of subjects: 14
Study 11045437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study 11045437 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 12
Study 11045437 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 12
Study 11045437 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 12
Study 10203399 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-telephone
Number of subjects: 233
Study 10203399 — intervention group
Group type: COMPARATOR
Intervention: No model-telephone (control)
Number of subjects: 233
Study 8450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (slow training) trained for 8 weeks at 1.05 rad s‐1
Number of subjects: 34
Study 8450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (fast training) trained for 8 weeks at 3.14 rad s‐1
Number of subjects: 34
Study 8450590 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (periodized training) trained for 5 weeks at 1.05 rad s‐1 and 3 weeks at 3.14 rad s‐1
Number of subjects: 34
Study 8450590 — intervention group
Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 34
Study 3102991 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF (growth hormone-releasing factor)
Number of subjects: 30
Study 3102991 — intervention group
Group type: COMPARATOR
Intervention: TRH (thyrotropin-releasing hormone)
Number of subjects: 30
Study 3102991 — intervention group
Group type: EXPERIMENTAL
Intervention: GRF plus TRH
Number of subjects: 30
Study 3102991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 9310525 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 746
Study 9310525 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 746
Study 30902532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Marrow Venting Procedure (BMVP)
Number of subjects: 40
Study 30902532 — intervention group
Group type: COMPARATOR
Intervention: Meniscal repair only (Control)
Number of subjects: 40
Study 30056615 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 129
Study 30056615 — intervention group
Group type: COMPARATOR
Intervention: Alternative family therapy (Control)
Number of subjects: 129
Study 26511012 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC levels measured at baseline, 3 months, and 12 months
Number of subjects: 117
Study 24374901 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib treatment
Number of subjects: 25
Study 24374901 — intervention group
Group type: COMPARATOR
Intervention: healthy subjects
Number of subjects: 25
Study 22745145 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2x600 mg/day for 8 weeks
Number of subjects: 32
Study 19622077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid MRSA screening
Number of subjects: 12682
Study 19622077 — intervention group
Group type: COMPARATOR
Intervention: Standard culture method
Number of subjects: 12682
Study 17427172 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraselective transarterial chemoembolization (STACE)
Number of subjects: 60
Study 17427172 — intervention group
Group type: COMPARATOR
Intervention: Conventional transarterial chemoembolization (TACE)
Number of subjects: 60
Study 15583702 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val/Val genotype
Number of subjects: 120
Study 15583702 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT gene
Number of subjects: 120
Study 11893973 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL 0.5% bupivacaine solution
Number of subjects: 34
Study 11893973 — intervention group
Group type: COMPARATOR
Intervention: 10 mL normal saline (placebo)
Number of subjects: 34
Study 10462334 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention program
Number of subjects: 20
Study 10462334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7843752 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertensive subjects (category II)
Number of subjects: 0
Study 7843752 — intervention group
Group type: COMPARATOR
Intervention: Subjects with successful antihypertensive therapy (category III)
Number of subjects: 0
Study 7843752 — intervention group
Group type: COMPARATOR
Intervention: Subjects who remained hypertensive despite drug therapy (category IV)
Number of subjects: 0
Study 2192572 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide 0.1 mg/kg
Number of subjects: 46
Study 2192572 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.1 mg/kg
Number of subjects: 46
Study 2192572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 350940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (600 mg/day for 10 days)
Number of subjects: 29
Study 350940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30792343 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS-containing triple therapy
Number of subjects: 0
Study 30792343 — intervention group
Group type: COMPARATOR
Intervention: Single or double maintenance therapy
Number of subjects: 0
Study 28655015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture plus clomiphene
Number of subjects: 1000
Study 28655015 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture plus clomiphene
Number of subjects: 1000
Study 28655015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture plus placebo
Number of subjects: 1000
Study 28655015 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture plus placebo
Number of subjects: 1000
Study 28655015 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 1000
Study 28655015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 1000
Study 28655015 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 1000